» Authors » Bernard Roubert

Bernard Roubert

Explore the profile of Bernard Roubert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 1377
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Pennell D, Porter J, Cappellini M, Chan L, El-Beshlawy A, Aydinok Y, et al.
Haematologica . 2010 Nov; 96(1):48-54. PMID: 21071497
Background: The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of...
22.
Lee J, Yoon S, Shen Z, Ganser A, Hsu H, Habr D, et al.
Blood . 2010 Jun; 116(14):2448-54. PMID: 20566896
The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety...
23.
Gattermann N, Finelli C, Porta M, Fenaux P, Ganser A, Guerci-Bresler A, et al.
Leuk Res . 2010 May; 34(9):1143-50. PMID: 20451251
The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1...
24.
Pennell D, Porter J, Cappellini M, El-Beshlawy A, Chan L, Aydinok Y, et al.
Blood . 2009 Dec; 115(12):2364-71. PMID: 19996412
Cardiac iron overload causes most deaths in beta-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac iron overload was assessed in 192 patients with beta-thalassemia in a 1-year...
25.
Cappellini M, Porter J, El-Beshlawy A, Li C, Seymour J, Elalfy M, et al.
Haematologica . 2009 Dec; 95(4):557-66. PMID: 19951979
Unlabelled: Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses....